The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7529-7539

  Ishida, Takashi ^a   Iida, Shinsuke ^a   Akatsuka, Yoshiki ^b   Ishii, Toshihiko ^a   Miyazaki, Mikinori ^a   Komatsu, Hirokazu ^a   Inagaki, Hiroshi ^a   Okada, Noriko ^a   Fujita, Teizo ^c   Shitara, Kenya ^d   Akinaga, Shiro ^d   Takahashi, Toshitada ^b   Utsunomiya, Atae ^e   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

^e IMAMURA BUN IN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CHEMOKINE RECEPTOR CCR4; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KM2760; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; FOXP3 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; T CELL LEUKEMIA; T CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENOTYPE; HUMANS; IMMUNOTHERAPY; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CHEMOKINE; RECEPTORS, IGG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 9344251670     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0983     Document Type: Article

References (54)

1. Kikuchi M, Jaffe ES, Ralfkiaer E, Adult T-cell leukaemia/lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p. 200-3.
2. Gill PS, Harrington WJ, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alpha and zidovudine. N Engl J Med 1995;332:1744-8.
3. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:182-6.
4. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Report from the Lymphoma Study Group (1984-1987). Br J Haematol 1991;79:428-37.
5. Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T-cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:15-20.
6. Grillo-Lopez AJ, White CA, Vams C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26:66-73.
7. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999;26:74-8.
8. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999;26:88-96.
9. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single agent-pivotal trial. Semin Oncol 1999;26:79-87.
10. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:52-7.
11. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84.
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
13. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Results of a phase III trial of bevacizumab in combination with bolus irinotecan, 5-fluourourasil, leucovorin as a first-line therapy in subjects with metastatic CRC, http://www.asco.org/hurwitz no 3646.
14. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-36.
15. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
16. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CCR4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res 2004;64:2127-33.
17. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma (ATLL): its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9:3625-34.
18. Naoe T, Akao Y, Yamada K, et al. Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. Cancer Genet Cytogenet 1988;34:77-88.
19. Gazdar AF, Carney D, Bunn PA, et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980;55:409-17.
20. Bunn PA, Foss FM. T-Cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cytaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl 1996;24:12-23.
21. Miyoshi I, Kubonishi I, Yoshimoto S, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature (Lond.) 1981;294:770-1.
22. 3H] thymidine incorporation into cDNA in cultured Molt-4F cells. Jpn J Exp Med 1983;53:187-94.
23. Okamura S, Chechik BE, Lee C, Gelfand EW, Mak TW. Heterogeneity of human thymocytes and a malignant T-lymphoblastic cell line, MOLT-3. Cancer Res 1981;41:1664-8.
24. Emi N, Kitaori K, Seto M, Ueda R, Saito H, Takahashi T. Isolation of a novel cDNA clone showing marked similarity to ME491/CD63 superfamily. Immunogenetics 1993;37:193-8.
25. Akatsuka Y, Goldberg TA, Kondo E, et al. Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 2002;59:502-11.
26. Kondo E, Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002;169:2164-71.
27. Fujita T, Inoue T, Ogawa K, Iida K, Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987;166:1221-8.
28. Hideshima T, Okada N, Okada H. Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology 1990;69:396-401.
29. Ishida T, Inagaki H, Utsunomiya A, et al. CXCR3 and CCR4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004;10:5494-500.
30. Sakaguchi S, Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
31. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-22.
32. Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;6:389-400.
33. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha chains (CD25). Break down of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
34. Hori S, Nomura T, Sakaguchi S. Control of regulatory T-cell development by the transcription factor FoxP3. Science (Wash. DC) 2003;299:1057-61.
35. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
36. Ozaki S, Kosaka M, Wakahara Y, et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999;93:3922-30.
37. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
38. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of Fc gammaRIIIa (CD16) alters receptors function and predisponses to autoimmune disease. J Clin Investig 1997;100:1059-70.
39. Carton G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
40. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc{gamma}RIIIa polymorphism do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-4.
41. Sagara Y, Ishida C, Inoue Y, Shiraki H, Maeda Y. 71-Kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J Virol 1998;72:535-41.
42. Lo KM, Vivier E, Rochet N, et al. Infection of human natural killer (NK) cells with replication-defective human T-cell leukemia virus type I provirus. Increased proliferative capacity and prolonged survival of functionally competent NK cells. J Immunol 1992;149:4101-8.
43. Yoshikura H, Nishida J, Yoshida M, Kitamura Y, Takaku F, Ikeda S. Isolation of HTLV derived from Japanese adult T-cell leukemia patients in human diploid fibroblast strain IMR90 and the biological characteristics of the infected cells. Int J Cancer 1984;33:745-9.
44. Yamamoto N, Matsumoto T, Koyanagi Y, Tanaka Y, Hinuma Y. Unique cell lines harbouring both Epstein-Barr virus and adult T-cell leukaemia virus, established from leukemia patients. Nature (Lond.) 1982;299:367-9.
45. Hoxie JA, Matthews DM, Cines DB. Infection of human endothelial cells by human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1984;81:7591-5.
46. Clapham P, Nagy K, Cheingsong-Popov R, Exley M, Weiss RA. Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line. Science (Wash. DC) 1983;222:1125-7.
47. Nagafuji K, Harada M, Teshima T, et al. Hematopoietic progenitor cells from patients with adult T-cell leukemia-lymphoma are not infected with human T-cell leukemia virus type 1. Blood 1993;82:2823-8.
48. Fujihara K, Itoyama Y, Yu F, Kubo C, Goto I. Cellular immune surveillance against HTLV-1-infected T lymphocytes in associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neurol Sci 1991;105:99-107.
49. Yu F, Itoyama Y, Fujihara K, Goto I. Natural killer (NK) cells in HTLV-1-associated myelopathy/tropical spastic paraparesis-decreases in NK cells subset population and activity in HTLV-1 seropositive individuals. J Neuroimmunol 1991;33:121-8.
50. Yamamoto N, Okada M, Koyanagi Y, Kannagi M, Hinuma Y. Transformation of human leukocytes by cocultivation with an adult T-cell leukemia virus producer cell line. Science (Wash. DC) 1982;217:737-9.
51. Kozuru M, Uike N, Takeichi N, et al. The possible mode of escape of adult T-cell leukaemia cells from antibody-dependent cellular cytotoxicity. Br J Haematol 1989;72:502-6.
52. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-62.
53. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685-91.
54. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.